Stock analysis, price data, and AI-powered insights for Biogen (BIIB).
Biogen operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for BIIB.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). BIIB Stock Intelligence Report. [stoxpulse.com/stocks/biib]
Disclaimer: The information on this page about Biogen (BIIB) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Biogen.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 18%
Jun 30
HAWKINS bought 2K shares
Jun 9
SHERWIN bought 2K shares
Jun 9
HC Wainwright & Co. Maintains Buy on Biogen, Raise...
9h ago
Morgan Stanley Maintains Equal-Weight on Biogen, R...
10h ago
StoxPulse AI results for BIIB: Pulse Score 54/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$30.70B
P/E Ratio
20.0
EPS
$-0.33
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Sep 25
+21.5%
Dec 25
+20.9%
Mar 26
+26.3%
Jun 26
+18.0%
Beat estimates 4 of 4 quarters (100%)
Sector
Healthcare
Industry
Biotechnology
HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251
Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231
RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248
TD Cowen Maintains Buy on Biogen, Raises Price Target to $225
Wedbush Maintains Neutral on Biogen, Raises Price Target to $215
Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?
Why Biogen Stock Topped the Market Today